Q4 2021 Results slide image

Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Respiratory & Allergy 110 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine
View entire presentation